These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22728115)

  • 1. Optimising existing therapeutic strategies for the treatment of non-muscle-invasive bladder cancer: the role of intensive neoadjuvant intravesical mitomycin C.
    Bryan RT
    Eur Urol; 2012 Nov; 62(5):803-5. PubMed ID: 22728115
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Renzo Colombo, Lorenzo Rocchini, Nazareno Suardi, et al. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. Eur Urol 2012;62:797-802.
    Garg M; Goel A; Prakash J
    Eur Urol; 2013 Jan; 63(1):e6. PubMed ID: 23021089
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to Manish Garg, Apul Goel and Jai Prakash's letter to the editor re: Renzo Colombo, Lorenzo Rocchini, Nazareno Suardi, et al. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. Eur Urol 2012;62:797-802.
    Colombo R; Rocchini L; Suardi N; Benigni F; Colciago G; Bettiga A; Pellucchi F; Maccagnano C; Briganti A; Salonia A; Rigatti P; Montorsi F
    Eur Urol; 2013 Jan; 63(1):e7-8. PubMed ID: 23092542
    [No Abstract]   [Full Text] [Related]  

  • 4. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
    Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
    Mangiarotti B; Trinchieri A; Del Nero A; Montanari E
    Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor. T. Maeda, E. Kikuchi, K. Matsumoto, A. Miyajima and M. Oya. J Urol 2011; 185: 802-806.
    Serretta V
    J Urol; 2011 Oct; 186(4):1557. PubMed ID: 21855916
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of Large Non-Muscle-Invasive Bladder Cancer: The Potential Role of Neoadjuvant Intravesical Chemotherapy.
    Raber M; Buchholz N; Vercesi A; Hendawi NA; Inneo V; Di Paola G; Tessa L; Gazzano G; Viglio A; Hasan IM
    Urol Int; 2021; 105(3-4):298-303. PubMed ID: 33333529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
    Di Stasi SM; Liberati E; Dutto L; Verri C
    Arch Ital Urol Androl; 2008 Dec; 80(4):157-61. PubMed ID: 19235432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor.
    Maeda T; Kikuchi E; Matsumoto K; Miyajima A; Oya M
    J Urol; 2011 Mar; 185(3):802-6. PubMed ID: 21239010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma.
    Kalsi J; Harland SJ; Feneley MR
    Expert Opin Drug Deliv; 2008 Jan; 5(1):137-45. PubMed ID: 18095933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recirculant hyperthermic IntraVEsical chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer.
    Sousa A; Piñeiro I; Rodríguez S; Aparici V; Monserrat V; Neira P; Carro E; Murias C; Uribarri C
    Int J Hyperthermia; 2016 Jun; 32(4):374-80. PubMed ID: 26915466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intravesical instillation for bladder tumors].
    Rivière A; Ploussard G; Desgranchamps F
    Rev Prat; 2014 Dec; 64(10):1388-9. PubMed ID: 25665319
    [No Abstract]   [Full Text] [Related]  

  • 13. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer.
    Mostafid AH; Rajkumar RG; Stewart AB; Singh R
    BJU Int; 2006 Mar; 97(3):509-12. PubMed ID: 16469017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer.
    Besarani D; Al-Akraa M
    BJU Int; 2006 Jul; 98(1):232-3. PubMed ID: 16831177
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
    O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
    BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection.
    Shapiro O; Jones K; Wang C; Landas S; Haas GP
    Can J Urol; 2006 Dec; 13(6):3317-20. PubMed ID: 17187694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer].
    Rouprêt M; Neuzillet Y; Larré S; Pignot G; Coloby P; Rébillard X; Mongiat-Artus P; Chartier-Kastler E; Soulié M; Pfister C;
    Prog Urol; 2012 Nov; 22(15):920-31. PubMed ID: 23102014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression.
    Maffezzini M; Campodonico F; Canepa G; Manuputty EE; Tamagno S; Puntoni M
    Cancer Chemother Pharmacol; 2014 May; 73(5):925-30. PubMed ID: 24585046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent verrucous carcinoma of the urinary bladder after transurethral resection followed by intravesical mitomycin, and a review of the literature.
    Hassan M; Qureshi A; Nasir H
    BMJ Case Rep; 2016 Jun; 2016():. PubMed ID: 27307433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.